NCT05352165 - The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Neoadjuvant Therapy

Interventions

DRUG

standard long-term therapy

The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.

DRUG

FOLFOX and standard long-term radiotherapy

FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity

DRUG

FOLFIRI and standard long-term radiotherapy

FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity

DRUG

5-FU and standard long-term radiotherapy

5-FU and standard long-term radiotherapy based on organoids drug sensitivity

DRUG

5-FU and pembrolizumab and standard long-term radiotherapy

5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity

DRUG

Other individualized treatments

Other individualized treatments based on organoids drug sensitivity

All Listed Sponsors

collaborator

Shanghai OneTar Biomedicine Co., Ltd.

UNKNOWN

collaborator

Ruijin Hospital

OTHER

lead

Shanghai Minimally Invasive Surgery Center

OTHER